Biogen Inc. investors will have another chance to prove some of their claims that the pharmaceutical company violated federal securities laws in the way it presented data about the efficacy of its expensive Alzheimer’s drug, Aduhelm.
Allie Reed is a health care reporter who covers a wide range of topics related to the health care industry. She has written for various publications including Bloomberg Law, BNN Bloomberg, Bloomberg News, and the Los Angeles Times. With a focus on providing accurate and informative reporting, Allie's articles delve into the legal, financial, and regulatory aspects of the health care sector.